Reducing Reintubation Risk in High-Risk Cardiac Surgery Patients With High-Flow Nasal Cannula
Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Mar 1, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to reduce the chances of needing to put a breathing tube back in (reintubation) for patients who have just undergone heart surgery. The researchers want to compare two groups of patients: one group will receive oxygen therapy using high-flow nasal cannulas (which are soft tubes that deliver oxygen through the nose), while the other group will receive the usual care chosen by their healthcare team. The goal is to see which method leads to better outcomes after surgery.
To be eligible for this study, participants need to be adults aged 18 and older who have had heart surgery that lasted at least three hours and were on a breathing machine when they arrived at the intensive care unit. They also need to be expected to have their breathing tube removed at some point while in the unit. Those who meet these criteria will have the opportunity to help researchers understand how to improve care for heart surgery patients. Participants can expect to be monitored closely during their recovery and may experience different methods of receiving oxygen as part of the trial.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Age ≥18 years
- • Undergoing cardiac surgery, defined as a documented surgical service of "cardiac surgery" in the electronic health record, performed in the main operating rooms at Vanderbilt University Medical Center
- • Admitted to the cardiovascular intensive care unit postoperatively with an endotracheal tube in place and mechanically ventilated
- • Surgery duration (documented time between "Anesthesia start" and "Anesthesia stop" in the EHR) of at least 180 minutes
- • Received an order to be extubated by a treating provider o Patients who meet all other criteria but do not receive an order to extubate will be randomized but not enrolled
- • Exclusion Criteria
- • • Patient does not meet inclusion criteria
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Trial Officials
Robert E Freundlich, MD
Principal Investigator
Vanderbilt University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials